


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant(s): Walke et al.

Application No.: 09/735,713

Filed: December 12, 2000

Group Art Unit: 1745

Title: Novel Human Proteases and
Polynucleotides Encoding the Same

Examiner: Not Yet Assigned

Attorney Docket No.: LEX-0108-USA

Assistant Commissioner for Patents
Washington, D.C. 20231
Box DD

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

X under 37 CFR 1.97(b), or

(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

— under 37 CFR 1.97(c) together with either a:

— Certification under 37 CFR 1.97(e), or

— a \$240.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

— under 37 CFR 1.97(d) together with a:

— Certification under 37 CFR 1.97(e), and

— a petition under 37 CFR 1.97(d)(2)(ii), and

— a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

RECEIVED
DEC 20 2001
TC 1700

The relevance of several of the attached references are that they were cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

12-7-01
Date

Lance K. Ishimoto by David W. Habler REG. NO. 41,071
Lance K. Ishimoto Reg. No. 41,866

LEXICON GENETICS INCORPORATED
4000 Research Forest Drive
The Woodlands, TX 77381
(281) 863-3333